Hopewell Therapeutics to Present Data Highlighting Novel Tissue Targeting Lipid Nanoparticles at the American Society of Gene and Cell Therapy 27th Annual Meeting
Hopewell has advanced product candidates that combine tissue-targeting LNPs with proprietary mRNA encoding for therapeutic proteins to treat rare and common diseases.
- Hopewell has advanced product candidates that combine tissue-targeting LNPs with proprietary mRNA encoding for therapeutic proteins to treat rare and common diseases.
- These immune targeting LNPs have been successfully deployed in preclinical cancer vaccine and infectious disease vaccine models.
- "This is an exciting time for Hopewell," shared Louis Brenner, M.D., Hopewell's President and CEO.
- Our team is presenting data this week that showcase the progress of our ttLNPs and potential therapeutic applications that could be pursued for patient benefit."